Clinical research & concentration reference

Mazdutide Research & Reconstitution: BAC Water, Studies & Evidence

Mazdutide is a once-weekly dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist developed for metabolic disease and weight management. Unlike tirzepatide, which targets GIP and GLP-1 receptors, mazdutide combines GLP-1 receptor activity with glucagon receptor activity. This page separates regulatory status, human clinical-trial evidence, studied doses and mathematical concentration examples.

CHINA APPROVED CLINICAL EVIDENCE FDA NOT APPROVED RESEARCH CONCENTRATION

Clinical Research Snapshot

Compound Mazdutide
Development code IBI362
Drug / compound class Dual glucagon receptor (GCGR) and GLP-1 receptor agonist
Mechanism Co-agonism at GLP-1 and glucagon receptors
FDA regulatory status Not FDA approved as of September 11, 2026
International regulatory status Approved in China for specified weight-management and type 2 diabetes indications
Clinical development phase Phase 3 completed in multiple Chinese obesity and diabetes programs; additional clinical research continues
Human evidence level High and expanding — phase 3 randomized controlled trials plus newer international phase 2 evidence
Administration route studied Subcutaneous injection, generally once weekly
Key research areas Obesity, overweight, type 2 diabetes and other metabolic conditions

Mazdutide Dual-Receptor Mechanism

Mazdutide Dual-Receptor Activity GLP-1 receptor GLUCAGON receptor Mazdutide GLP-1 activity • glucagon activity • metabolic research
Simplified educational illustration of mazdutide's two receptor targets.
Mazdutide Clinical Evidence PHASE 2 Early obesity GLORY-1 Obesity GLORY-2 9 mg research GLOBAL Continued trials Randomized human clinical evidence
Simplified map of major clinical-development milestones.

Mazdutide BAC Water & Concentration Reference

Reconstitution requirements are formulation-specific. Mazdutide clinical trials have generally used supplied injectable drug presentations rather than establishing a universal BAC-water preparation procedure for an unrelated research vial.

Important formulation distinction. BacScience does not present BAC-water mixing as an approved preparation method for commercial mazdutide products. If a separate research material is supplied as a lyophilized vial, its preparation requirements depend on that specific material, formulation and experimental protocol.

Research Concentration Examples — Mathematical Reference

The governing mathematical relationship is:

Total vial quantity ÷ liquid volume = concentration

Example: a hypothetical 10 mg research vial with a 2 mL final liquid volume produces a mathematical concentration of 5 mg/mL.

Research vial quantity Liquid volume Calculated concentration Mathematical interpretation
4 mg 1 mL 4 mg/mL 0.1 mL mathematically contains 0.4 mg
6 mg 1 mL 6 mg/mL 0.1 mL mathematically contains 0.6 mg
9 mg 1.5 mL 6 mg/mL 0.1 mL mathematically contains 0.6 mg
10 mg 2 mL 5 mg/mL 0.1 mL mathematically contains 0.5 mg
16 mg 2 mL 8 mg/mL 0.1 mL mathematically contains 0.8 mg
20 mg 4 mL 5 mg/mL 0.1 mL mathematically contains 0.5 mg

Calculate a Custom Concentration

Enter the vial quantity and liquid volume in the BacScience universal BAC-water calculator.

Open BAC Water Calculator

What Is Mazdutide?

Mazdutide, also known by its development code IBI362, is a once-weekly dual agonist of the glucagon-like peptide-1 receptor and glucagon receptor.

The compound was developed for metabolic conditions including obesity, overweight and type 2 diabetes. Its clinical-development program has included randomized phase 2 and phase 3 trials in Chinese populations and more recent international research.

Mazdutide differs mechanistically from GLP-1 receptor-only agents because it combines GLP-1 receptor signaling with glucagon receptor activation.

Mechanism of Action

Mazdutide activates both the GLP-1 receptor and glucagon receptor. GLP-1 receptor signaling is associated with glucose-dependent insulin secretion, appetite regulation and gastrointestinal effects, while glucagon receptor activity is involved in hepatic metabolic signaling and energy expenditure.

The dual mechanism is being investigated as a way of combining glucose-lowering and weight-reduction effects through two related but distinct metabolic pathways.

Mechanistic distinction: Mazdutide is a GLP-1/glucagon dual agonist. It is not a GIP/GLP-1 dual agonist such as tirzepatide.

FDA / Regulatory Status

Mazdutide is not FDA approved in the United States as of September 11, 2026.

Mazdutide received its first regulatory approval in China in June 2025 for long-term body-weight management in eligible adults with overweight or obesity. It subsequently received approval in China for glycemic control in adults with type 2 diabetes.

Regulatory distinction: Chinese approval does not constitute FDA approval in the United States. Approved indications and product labeling are jurisdiction- specific.

Approved vs. Investigational Uses

China-approved indications Long-term body-weight management in eligible adults with overweight or obesity, and glycemic control in adults with type 2 diabetes.
Investigational areas Additional research continues in obesity-related and metabolic conditions, including studies outside currently approved indications.

Approved Dosage vs. Doses Studied in Clinical Trials

Regulatory labeling Mazdutide has jurisdiction-specific approved labeling in China. Approved product schedules should be interpreted using the applicable Chinese regulatory product information rather than U.S. FDA labeling.
Clinical-trial doses Published trials have studied 3 mg, 4 mg, 4.5 mg, 6 mg, 9 mg, 10 mg and 16 mg regimens in different study designs. A studied dose is not automatically a recommended dose.

Mazdutide Clinical Development History

Early clinical development evaluated mazdutide in obesity and overweight populations using lower-dose weekly regimens. A phase 2 randomized trial published in 2023 evaluated 3 mg, 4.5 mg and 6 mg once weekly in Chinese adults with overweight or obesity.

The GLORY program subsequently moved into phase 3 development. GLORY-1 evaluated 4 mg and 6 mg in Chinese adults with overweight or obesity, while GLORY-2 evaluated 9 mg in adults with obesity.

Additional phase 3 work has evaluated mazdutide in type 2 diabetes, while international phase 2 research has investigated higher doses including 10 mg and 16 mg.

Major Human Clinical Trials

The table below prioritizes published randomized clinical evidence and major registered phase 3 programs. Dose and outcome information is study-specific and should not be interpreted as individualized treatment guidance.

Trial Phase Population N Dose Studied Route Frequency Duration Primary Outcome / Key Finding Source
Mazdutide Phase 2 Obesity Trial 2 Chinese adults with overweight or obesity 248 3, 4.5, 6 mg SC Weekly 24 weeks Mean body-weight changes were approximately −6.7%, −10.4% and −11.3% with 3 mg, 4.5 mg and 6 mg, respectively, versus approximately +1.0% with placebo. PubMed
GLORY-1 3 Chinese adults with overweight or obesity 610 4 mg, 6 mg SC Weekly 48 weeks At week 48, mean body-weight changes were approximately −11.00% with 4 mg, −14.01% with 6 mg and +0.30% with placebo. PubMed
GLORY-2 3 Chinese adults with obesity 461 9 mg SC Weekly 60 weeks Mean body-weight change at week 60 was −16.65% with mazdutide versus −1.50% with placebo. PubMed
Mazdutide T2D Monotherapy 3 Chinese adults with type 2 diabetes 320 4 mg, 6 mg SC Weekly 24 weeks + extension HbA1c reductions at week 24 were approximately −1.57% with 4 mg and −2.15% with 6 mg versus −0.14% with placebo. PubMed
Mazdutide vs Dulaglutide 3 Chinese adults with type 2 diabetes 731 4 mg, 6 mg vs dulaglutide 1.5 mg SC Weekly 28 weeks Both mazdutide doses demonstrated superiority to dulaglutide 1.5 mg for HbA1c reduction and greater body-weight reduction. PubMed
U.S. Obesity Phase 2 2 U.S. adults with overweight or obesity without type 2 diabetes 179 3–6 mg, 10 mg, 16 mg SC Weekly 48 weeks At week 32, least-squares mean body-weight changes were approximately −7.3%, −15.6% and −18.1% for the 3–6 mg, 10 mg and 16 mg groups versus −0.9% with placebo. PubMed
PCOS Research 1/2 Obese female adults with PCOS Study-specific Study-specific SC Weekly 24 weeks Investigational research evaluating efficacy in obese adults with polycystic ovary syndrome. ClinicalTrials.gov

Doses Studied in Mazdutide Clinical Research

Mazdutide has been studied across a relatively broad dose range. The dose used depends on the clinical program, development stage and study population.

Research context Dose documented Status
Early obesity phase 2 3 mg, 4.5 mg and 6 mg once weekly TRIAL DOSES
GLORY-1 4 mg and 6 mg once weekly PHASE 3
GLORY-2 9 mg once weekly PHASE 3
Type 2 diabetes phase 3 4 mg and 6 mg once weekly PHASE 3
International phase 2 Up to 16 mg once weekly INVESTIGATIONAL
Dose interpretation: A dose appearing in a clinical trial describes that study's protocol. It is not automatically an approved dose, a universal maintenance dose, or an individualized recommendation.

Mazdutide Research Outcomes

Body Weight

In GLORY-1, once-weekly 4 mg and 6 mg mazdutide produced mean body-weight reductions of approximately 11.00% and 14.01% at week 48, respectively, compared with approximately 0.30% with placebo.

Higher-Dose Obesity Research

GLORY-2 evaluated a 9 mg regimen in Chinese adults with obesity. At week 60, mean body-weight change was approximately −16.65% with mazdutide compared with −1.50% with placebo.

Glycemic Control

In a phase 3 type 2 diabetes trial, mazdutide reduced HbA1c by approximately 1.57 percentage points with 4 mg and 2.15 percentage points with 6 mg at week 24, compared with approximately 0.14 percentage points with placebo.

Comparative Evidence

A phase 3 trial comparing mazdutide with dulaglutide found that both 4 mg and 6 mg mazdutide were noninferior and superior to dulaglutide 1.5 mg for the prespecified HbA1c outcome and produced greater weight reduction.

Higher-Dose International Research

A 2026 U.S. phase 2 trial evaluated mazdutide regimens including 10 mg and 16 mg. At week 32, the reported least-squares mean body-weight changes were approximately −15.6% with 10 mg and −18.1% with 16 mg versus −0.9% with placebo.

Adverse Events & Safety Findings

Across published mazdutide trials, gastrointestinal adverse events have been among the most frequently reported events. These include nausea, diarrhea, vomiting and appetite-related gastrointestinal symptoms.

In GLORY-1, the most frequently reported adverse events were gastrointestinal and were predominantly mild to moderate in severity.

In GLORY-2, vomiting, nausea and diarrhea were among the most common reported adverse events. The majority were described as mild or moderate.

Safety interpretation: Trial safety results are population- and protocol-specific. They should not be treated as a complete substitute for the current regulatory product information applicable to the jurisdiction where mazdutide is approved.

Research Limitations & What Remains Unknown

Much of the pivotal published mazdutide evidence has been generated in Chinese clinical populations. Results may not automatically generalize to other populations, healthcare systems or disease profiles.

The clinical-development program is also evolving. Higher-dose international studies provide additional information, but their results do not automatically establish regulatory approval.

Important unanswered questions include long-term comparative effectiveness, long-term safety surveillance across broader populations, optimal dose selection for different indications, durability after treatment discontinuation and the regulatory status of investigational indications.

BAC Water / Reconstitution Considerations

There is no universal BAC-water volume for "mazdutide" as a compound.

The correct liquid volume for a particular research material depends on the amount of material in the vial, desired final concentration, formulation characteristics and the applicable experimental protocol.

Commercial formulation distinction: Approved pharmaceutical presentations should be interpreted according to the applicable regulatory product information. Those instructions should not automatically be repurposed as directions for an unrelated lyophilized research vial.

General Concentration Formula

Total vial quantity ÷ final liquid volume = concentration

For example, 10 mg divided by 2 mL equals 5 mg/mL mathematically. This is a concentration calculation only and is not a preparation, dosing or administration recommendation.

Mazdutide Reconstitution Calculator

Use the universal BacScience calculator for concentration mathematics.

Calculate Concentration

Mazdutide Research FAQ

What is mazdutide?

Mazdutide, also known as IBI362, is a once-weekly dual agonist of the GLP-1 receptor and glucagon receptor developed for metabolic conditions including obesity, overweight and type 2 diabetes.

Is mazdutide FDA approved?

No. Mazdutide is not FDA approved in the United States as of September 11, 2026. It has received regulatory approval in China for specified indications.

Is mazdutide approved anywhere?

Yes. Mazdutide received its first approval in China in 2025 for long-term weight management in eligible adults with overweight or obesity and subsequently for glycemic control in adults with type 2 diabetes.

What receptors does mazdutide target?

Mazdutide activates both the GLP-1 receptor and glucagon receptor.

What mazdutide doses have been studied?

Published and registered studies have evaluated multiple regimens, including 3 mg, 4 mg, 4.5 mg, 6 mg, 9 mg, 10 mg and 16 mg in different clinical-development programs.

What was studied in GLORY-1?

GLORY-1 evaluated once-weekly 4 mg and 6 mg mazdutide versus placebo in Chinese adults with overweight or obesity over 48 weeks.

What was studied in GLORY-2?

GLORY-2 evaluated once-weekly 9 mg mazdutide versus placebo in Chinese adults with obesity over 60 weeks.

How much BAC water should be used for mazdutide?

There is no single universal BAC-water volume for every mazdutide research material. Concentration is determined mathematically by the total compound quantity divided by the final liquid volume. The appropriate preparation method depends on the specific formulation and experimental protocol.

How do you calculate mazdutide concentration?

Divide the total quantity of compound by the final liquid volume. For example, 10 mg divided by 2 mL equals 5 mg/mL mathematically.

What is the highest mazdutide dose studied in published clinical research?

Published 2026 international phase 2 research has evaluated a 16 mg once-weekly regimen. This is a clinical research dose and should not be interpreted as an FDA-approved or individualized treatment recommendation.

What are the most common adverse events reported with mazdutide?

Gastrointestinal adverse events, including nausea, diarrhea and vomiting, are among the most frequently reported events across clinical studies.

Where should researchers verify the latest mazdutide evidence?

Use applicable regulatory documents, ClinicalTrials.gov, PubMed and the original peer-reviewed clinical-trial publication when available.

Scientific References

  1. Ji L, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine. 2025. PubMed .
  2. Ji L, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine. NEJM .
  3. Ji L, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications. 2023. PubMed .
  4. Gao L, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026. PubMed .
  5. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Phase 3 clinical trial. PubMed .
  6. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Phase 3 randomized clinical trial. PubMed .
  7. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based multicentre phase 2 randomized trial. Lancet Diabetes & Endocrinology. 2026. PubMed .
  8. ClinicalTrials.gov. GLORY-2 — NCT06164873. ClinicalTrials.gov .
  9. ClinicalTrials.gov. Mazdutide PCOS research — NCT06519656. ClinicalTrials.gov .
  10. Mazdutide: First Approval. Drugs. 2025. PubMed .
Last scientifically reviewed: September 11, 2026.

This page is an educational clinical-research reference. It is not medical advice, a prescribing guide, or a substitute for applicable regulatory product information. Clinical-trial doses and mathematical concentration examples should not be interpreted as individualized treatment or administration recommendations.